CJC-1295: How It Works, What It's Studied For & Safety
CJC-1295 is a growth-hormone-releasing-hormone (GHRH) analog studied for sustained stimulation of the body's own pulsatile GH and IGF-1 release. Clinicians consider it for endogenous growth-hormone axis support in adults. It is not FDA-approved as a finished drug product and is dispensed by Wells Pharmacy Network only after a licensed clinician evaluates intake, history, and labs.
Also known as: Modified GRF (1-29), DAC:GRF
How does CJC-1295 work?
CJC-1295 is a synthetic GHRH (1-29) analog modified to resist enzymatic degradation. The DAC (drug-affinity-complex) version covalently binds plasma albumin, dramatically extending its half-life and producing prolonged, low-amplitude elevation in GH and IGF-1 - distinct from exogenous HGH administration.
What is CJC-1295 studied for?
- Endogenous growth-hormone axis support in adults
- Pairing with growth-hormone secretagogues (Ipamorelin, Hexarelin) in body-composition protocols
- Sleep architecture research where slow-wave sleep is the target
How is CJC-1295 taken?
Compounded as a subcutaneous injection. Non-DAC ('Mod GRF 1-29') is dosed multiple times per week; DAC versions are dosed weekly. Clinician-directed cycles run several months with periodic IGF-1 monitoring.
Is CJC-1295 FDA-approved? Is it safe?
Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. Common research-reported effects include injection-site reactions and transient flushing. Not appropriate for patients with active malignancy or untreated diabetic retinopathy. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.
In the Regen Therapy catalog
This compound does not currently appear in an active Regen Therapy protocol. Browse the full catalog for adjacent options.
What does the research say about CJC-1295?
Phase-1 and phase-2 pharmacology in healthy adults established the dose-dependent, sustained IGF-1 elevation profile; no FDA approval for adult GH-axis support exists.
Citations & further reading
Considering CJC-1295 as part of a protocol?
Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.
Browse the catalog →